Bio-link Australia Pty. Ltd.

Actinogen announces successful completion of interim analysis & $15m raise

Bio-Link client Actinogen Medical announced that an independent Data Safety and Monitoring Board completed a planned interim analysis of its phase II Alzheimer’s trial of Xanamem and recommended continuation of the trial without modification (link), together with a $15M placement by leading investors including biotechnology value fund (link). Learn more about Xanamem.